Solana (NASDAQ:HSDT) Posts Earnings Results, Misses Estimates By $0.03 EPS

Solana (NASDAQ:HSDT) posted its quarterly earnings data on Friday. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03), Zacks reports. Solana had a negative return on equity of 67.57% and a negative net margin of 1,427.15%.The company had revenue of $2.53 million for the quarter, compared to analysts’ expectations of $3.50 million.

Here are the key takeaways from Solana’s conference call:

• Institutional infrastructure launched: Solana Company’s first validated cluster is operational in Tokyo, with approximately 500,000 SOL in committed third-party stake and validator-related revenue expected to begin in the third quarter.
• Staking performance remained strong: The company generated $2.5 million, or 31,200 SOL, in second-quarter staking revenue and achieved a 6.14% net annualized yield versus a network average of approximately 5.68%.
• Legacy-business transition advanced: The cash-consuming medical-device business was divested, while the company completed its acquisition of a Hong Kong regulated trust company on July 15 for $2 million to support its Asia-Pacific institutional strategy.
• GAAP losses remained substantial: The company reported a $30.3 million second-quarter net loss, including a $25.4 million realized loss on digital assets, while general and administrative expenses rose to $11.1 million, although management expects costs to decline as divestiture-related expenses end.
• Capital allocation will remain valuation-dependent: Solana Company repurchased $2.3 million of shares during the quarter while trading below net asset value, but management said future buybacks, SOL purchases, or business investment will depend on which option offers the greatest SOL-per-share accretion.

Solana Price Performance

Shares of NASDAQ HSDT traded down $0.10 during midday trading on Friday, hitting $1.70. The company’s stock had a trading volume of 137,150 shares, compared to its average volume of 106,755. The business’s fifty day simple moving average is $1.67 and its two-hundred day simple moving average is $1.95. Solana has a 1 year low of $1.19 and a 1 year high of $25.50. The firm has a market capitalization of $99.26 million, a price-to-earnings ratio of -0.02 and a beta of 1.01.

Institutional Investors Weigh In On Solana

Large investors have recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new stake in Solana during the 4th quarter worth approximately $140,000. Cetera Investment Advisers acquired a new position in shares of Solana in the fourth quarter worth $347,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Solana in the fourth quarter worth $46,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Solana in the fourth quarter worth $88,000. Finally, Marshall Wace LLP purchased a new stake in shares of Solana during the fourth quarter worth $195,000. 18.63% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on HSDT shares. Wall Street Zen lowered Solana from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings restated a “sell (e+)” rating on shares of Solana in a research report on Friday, July 17th. B. Riley Financial began coverage on Solana in a research note on Thursday, April 23rd. They issued a “buy” rating and a $3.00 price objective for the company. Finally, Zacks Research upgraded Solana to a “hold” rating in a report on Monday, April 27th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $3.50.

Solana News Summary

Here are the key news stories impacting Solana this week:

• Positive Sentiment: Management expects to receive its first validator-related rewards in the third quarter of 2026. The company has committed approximately 500,000 SOL to support its Tokyo validator cluster, potentially creating a new recurring revenue stream. Solana Company expects first validator-related rewards in Q3 2026
• Positive Sentiment: Second-quarter revenue rose to approximately $2.5 million from $43,000 a year earlier, primarily from staking. Solana Company also earned 31,200 SOL in staking rewards, completed its Tokyo institutional validator cluster, expanded in Asia-Pacific, and divested its legacy PoNS medical-device business. Solana Company Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company generated $7.9 million from a registered direct offering and repurchased approximately $2.3 million of shares during the quarter, retiring 1.3 million shares. Its partnership with the Jito Foundation and expansion across Asia-Pacific could support future institutional demand.
• Neutral Sentiment: Recent institutional activity was mixed: 17 investors added HSDT shares while 21 reduced positions in their latest reported quarters. BlackRock increased its position, but several other funds fully exited or substantially cut holdings. Solana Co insider and institutional activity
• Negative Sentiment: Quarterly results missed expectations. Revenue of about $2.53 million was below the $3.50 million consensus estimate, while reported adjusted EPS of negative $0.05 missed the expected negative $0.02. Solana Company Reports Q2 Loss, Lags Revenue Estimates
• Negative Sentiment: GAAP net loss widened to $30.3 million, driven partly by $25.4 million of realized digital-asset losses and sharply higher expenses. General and administrative costs reached $11.1 million, cash was only $3.6 million at quarter-end, and the accumulated deficit rose to $342.6 million.
• Negative Sentiment: Wall Street Zen downgraded HSDT to “Sell,” adding to investor caution around the company’s substantial losses, liquidity needs, and exposure to SOL price volatility. Wall Street Zen downgrades Solana Company

Solana Company Profile

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non?invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.